Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

BiVictriX Therapeutics PLC (BVX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
11.50 0.00    0.00%
26/04 - Closed. Currency in GBP ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 11.00 / 13.00
  • Day's Range: 11.50 - 11.68
Type:  Equity
Market:  United Kingdom
ISIN:  GB00BNXH3K91 
SEDOL:  BNXH3K9
BiVictriX Therapeutics 11.50 0.00 0.00%

BiVictriX Therapeutics Company Profile

 
Read the BiVictriX Therapeutics PLC company profile to learn more about the business and the management team. View BiVictriX Therapeutics PLC facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

17

Equity Type

ORD

BiVictriX Therapeutics plc is a United Kingdom-based drug discovery and development company focused on developing cancer therapeutics. The Company’s lead program, BVX001, is a Bi-Cygni antibody drug conjugate (ADC) designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with acute myeloid leukemia (AML), and in subpopulations of cancer cells from patients with other hematological cancers. The Company generates a pipeline of Bi-Cygni ADC therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints on tumor cells, which are largely absent from healthy cells. It has established a library of cancer-specific Bi-Cygni fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilizes these Bi-Cygni fingerprints, together with the Company’s ADC therapeutic design, to develop therapeutics to target cancers.

Contact Information

Address Alderley Park Alderley Edge
Cheshire Macclesfield, SK10 4TG
United Kingdom
Phone -
Fax -

Top Executives

Name Age Since Title
Robert Edward Hawkins 67 2021 Independent Non-Executive Director
Michael Glen Kauffman 60 2022 Non-Executive Chairman
William Drummond Paris 71 2021 Senior Independent Non-Executive Director
Tiffany Jane Thorn 35 2018 CEO & Executive Director
Susan Day Lowther 63 2021 Independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BVX Price Commentary

Write your thoughts about BiVictriX Therapeutics PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email